Download PDF here
WILMINGTON, Del., April 15, 2020 – DuPont (NYSE:DD) today launched a new program, #TyvekTogether, to increase the overall availability of Tyvek? personal protective garments in the company’s continued efforts to help combat the spread of COVID-19 and protect health care workers. At full capacity, this initiative could deliver 6 million additional non-surgical isolation gowns per month by enabling others to join us in protecting even more frontline responders.?
“There’s a critical need for protective apparel, and we believe that working with other companies to convert their existing cut-and-sew manufacturing capacity to protective garment fabrication is the fastest way to protect more people,” said John Richard, Vice President & General Manager of DuPont Safety Solutions. “Our dedicated employees around the world are working 24/7 to make more Tyvek? material and patterns available to more organizations, working together to protect those who are protecting us.”?
“Our dedicated employees around the world are working 24/7 to make more Tyvek??material and patterns available to more organizations, working together to protect those who are protecting us.”?
John Richard, Vice President & General Manager of DuPont Safety Solutions
DuPont has invested in equipment and technology to significantly increase its production of Tyvek? and Tychem? garments globally to meet the ever-increasing demand for personal protection equipment (PPE). Since January we have increased production of Tyvek??garments by more than 9 million garments per month specifically for COVID-19 response, which is more than double the amount produced for any prior crisis. The #TyvekTogether Program will introduce a new specialized Tyvek? ?fabric to enable an increase in the amount of garment production for the COVID-19 response to 15 million garments a month.?
?The #TyvekTogether Program includes the following components:
A new fabric, Tyvek? style 1222A, that has similar barrier properties to the core DuPontTM Tyvek? 400 garment offerings with adjusted fabric drape and hand to optimize material usage. ?
Tyvek? style 1222A is available in roll-good form to existing and new customers with available cut-and-sew capabilities to increase the total amount of Tyvek? garments available as quickly as possible. ??
DuPont will provide garment designs—including patterns and virtual manufacturing support—for a non-surgical isolation gown and a coverall that are optimized for simple and productive manufacturing.? With these patterns and technical assistance, we aim to accelerate the speed that new converters are able to begin producing PPE.?
Partners can also use their own designs for coveralls and garments to meet local needs.????
Additionally, DuPont will donate more than 57,000 Tyvek? coveralls?directly to the states in the US most impacted by COVID-19.??
The DuPont Personal Protection unit of DuPont Safety & Construction remains committed to helping to protect those who protect others, especially as we strive to protect the dedicated workers on the front lines fighting COVID-19. ?For more information about the #TyvekTogether program, visit ?tyvektogether.dupont.com.?
For more information about DuPont’s complete COVID-19 response efforts, please click here.
About DuPont Personal Protection?
From first responders to industrial workers, DuPont provides a wide range of personal protection solutions including some of the most trusted and innovative brands in the industry, such as Kevlar?, Nomex?, Tyvek?, and Tychem? to meet your safety needs. More information can be found at www.personalprotection.dupont.com
About DuPont Safety & Construction??
DuPont Safety & Construction is a global leader in delivering innovation for life’s essential needs in water, shelter and safety; enabling its customers to win through unique capabilities, global scale and iconic brands including Corian?, Kevlar?, Nomex?, Tyvek?, GreatStuff?, Styrofoam? and Filmtec?.?
DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life.? Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety.? More information can be found at www.tyuumokuannasui.com/.
Cautionary Statement Regarding Forward Looking Statements
This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.
On April 1, 2019, the company completed the separation of its materials science business into a separate and independent public company by way of a pro rata dividend-in-kind of all the then outstanding stock of Dow Inc. (the “Dow Distribution”). The company completed the separation of its agriculture business into a separate and independent public company on June 1, 2019, by way of a pro rata dividend-in-kind of all the then outstanding stock of Corteva, Inc. (the “Corteva Distribution”).
On December 15, 2019, DuPont and IFF announced they had entered definitive agreements to combine DuPont’s Nutrition & Biosciences business with IFF in a transaction that would result in IFF issuing shares to DuPont shareholders, pending customary closing conditions, other approvals including regulatory and that of IFF’s shareholders.
Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction with IFF; changes in relevant tax and other laws, (ii) failure to obtain necessary regulatory approvals, approval of IFF’s shareholders, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the proposed transaction with IFF, (iii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction with IFF, (iv) risks and costs and pursuit and/or implementation of the separation of the N&B Business, including timing anticipated to complete the separation, any changes to the configuration of businesses included in the separation if implemented, (v) risks and costs related to the Dow Distribution and the Corteva Distribution (together, the “Distributions”) including (a) with respect to achieving all expected benefits from the Distributions; (b) the incurrence of significant costs in connection with the Distributions, including costs to service debt incurred by the Company to establish the relative credit profiles of Corteva, Dow and DuPont and increased costs related to supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DuPont; (c) indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company ("Historical EID") in connection with the Corteva Distribution; and (d) potential liability arising from fraudulent conveyance and similar laws in connection with the Distributions; (vi) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (vii) uncertainty as to the long-term value of DuPont common stock; (viii) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade and (ix) other risks to DuPont's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Distributions; ability to effectively manage costs as the company’s portfolio evolves; the unpredictability and inherent uncertainty in duration and extent of events including security threats, such as acts of sabotage, terrorism or war; natural disasters and weather events and patterns; public health issues, epidemics and pandemics, including the novel coronavirus (COVID-19) and the responses thereto (such as voluntary and in some cases, mandatory quarantines as well as shut downs and other restrictions on travel and commercial, social and other activities) which could or could continue to result in a significant operational event for DuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's intellectual property rights; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks are and will be more fully discussed in DuPont's current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” (Part I, Item 1A) of DuPont’s 2019 Annual Report on Form 10-K as updated by DuPont’s subsequent periodic and current reports filed with the SEC.
#?? #?? #